[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638721":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":36,"responsibleParty":54,"collaborators":20,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":20,"enrollmentInfo":66,"targetDuration":20,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":81,"whyStopped":20,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"University Hospital Schleswig-Holstein","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Breast cancer patients treated with taxane-base chemotherapy","EXPERIMENTAL","Patients who were previously treated with taxane-base chemotherapy and adjuvant radiotherapy for breast cancer and developed either no or mild chemotherapy-induced peripheral neuropathy",[13],"Diagnostic Test: Symptom-based scoring system",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Symptom-based scoring system","The patients will be asked to complete the self-evaluation of symptoms and signs of neuropathy using a Neuropathy Tracker that questions symptoms quality, severity and distribution and guide the user through a systematic evaluation of pin-prick from a needle and vibration from the mobile on successive levels from the toes to the knee on both legs. Finally, the extension force or both great toes will be self-assessed by the participant. The self-examination is based on the structure of the Utah Early Neuropathy Score.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Dirk Rades, Prof. Dr. med., FASTRO","University of Luebeck, Germany","PRINCIPAL_INVESTIGATOR",[27,32],{"name":23,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","0049-451500","45400","Dirk.Rades@uksh.de",{"name":33,"role":28,"phone":29,"phoneExt":34,"email":35},"Maria K Streubel, Dr. rer. nat.","45420","MariaKarolin.Streubel@uksh.de",[37],{"facility":38,"status":20,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Department of Radiation Oncology, University of Luebeck","Lübeck","Schleswig-Holstein","23562","Germany","DE",{"type":45,"coordinates":46},"Point",[47,48],10.68729,53.86893,{"lat":48,"lon":47},[51,52],{"name":23,"role":28,"phone":29,"phoneExt":30,"email":31},{"name":33,"role":28,"phone":53,"phoneExt":34,"email":20},"0049.451-500",{"type":55,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100638721","chemotherapy-induced-peripheral-neuropathy---additional-evaluation-in-breast-cancer-survivors-100638721",false,"NCT07604441","Chemotherapy-Induced Peripheral Neuropathy - Additional Evaluation in Breast Cancer Survivors","Chemotherapy-induced Peripheral Neuropathy - Additional Evaluation of a Self-administered Scoring System for Breast Cancer Survivors","NEURO-BREAC-02","Inclusion Criteria:\n\n1. Histologically proven breast cancer\n2. Previous treatment with taxane-based chemotherapy followed by adjuvant radiotherapy\n3. Mild or no CIPN according to the Total Neuropathy Score\n4. Female gender\n5. Age ≥18 years\n6. Written informed consent\n7. Capacity of the patient to consent\n\nExclusion Criteria:\n\n1. Disease-related skin disorders of the lower extremities (e.g., related to skin infections, bullous dermatoses, dermatitis, papulo-squamous skin disorders, or urticaria\u002Ferythema)\n2. Pregnancy, Lactation\n3. Expected non-compliance","FEMALE","18 Years",{"count":67,"type":68},28,"ESTIMATED","INTERVENTIONAL",[71],"NA","The main goal of this trial is to identify the optimal cut-off score of a Scoring System to discriminate between mild chemotherapy-induced peripheral neuropathy (CIPN) and no CIPN in breast cancer survivors previously treated with taxane-based chemotherapy and adjuvant radiotherapy.",[74],"Breast Cancer",[76,77,78,79,80],"Breast cancer","Chemotherapy","Taxanes","Chemotherapy-induced peripheral neuropathy","Scoring system","NOT_YET_RECRUITING","2026-05-17",{"date":84,"type":85},"2026-05-22","ACTUAL",{"date":87,"type":68},"2026-06-01",{"date":89,"type":68},"2026-08-31",{"name":5,"class":6},1]